Journal of Ginseng Research

The Korean Society of Ginseng (고려인삼학회)
권호 표지
DOI QR코드

DOI QR Code

Intake of Korean Red Ginseng Extract and Saponin Enhances the Protection Conferred by Vaccination with Inactivated Influenza A Virus

  • Received : 2012.07.16
  • Accepted : 2012.07.25
  • Published : 2012.10.15
Download PDF
⟨ Previous Next ⟩

Abstract

Vaccination is the main strategy for preventing influenza infection. However, vaccine efficacy is influenced by several factors, including age and health status. The efficacy of the influenza vaccine is much lower (17% to 53%) in individuals over 65 yr of age compared with young adults (70% to 90%). Therefore, increasing vaccine efficacy remains a challenge for the influenza vaccine field. In this study, we investigated the impact of supplementing vaccination with the dietary intake of Korean red ginseng (RG) extract and RG saponin. Mice were immunized two times intranasally with inactivated influenza A (H1N1) virus. Mice received RG extract or RG saponin orally for 14 d prior to the primary immunization. After the primary immunization, mice continued to receive RG extract or RG saponin until the secondary immunization. Mice vaccinated in combination with dietary intake of RG extract and RG saponin showed elevated serum anti-influenza A virus IgG titers and improved survival rates in lethal influenza A virus infection: 56% and 63% of mice receiving RG extract or RG saponin survived, respectively, while 38% of mice that only received the vaccine survived. Moreover, mice receiving RG extract supplementation recovered their body weight more quickly than those not receiving RG extract supplementation. We propose that the dietary intake of RG extract and RG saponin enhances the vaccine-induced immune response and aids in providing protection against influenza virus infection.

Keywords

References

  1. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-344. https://doi.org/10.1001/jama.287.3.337
  2. Wee JJ, Park MK, Chung AS. Biological activities of ginseng and its application to human health. In: Benzie IF, Wachtel-Galor S, eds. Herbal medicine: biomolecular and clinical aspects. 2nd ed. Boca Raton: CRC Press, 2011. p. 157-174.
  3. Kim SK, Park JH. Trends in ginseng research in 2010. J Ginseng Res 2011;35:389-398. https://doi.org/10.5142/jgr.2011.35.4.389
  4. Ernst E. Panax ginseng: An overview of the clinical evidence. J Ginseng Res 2010;34:259-263. https://doi.org/10.5142/jgr.2010.34.4.259
  5. Lu JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 2009;7:293-302. https://doi.org/10.2174/157016109788340767
  6. Kim JY, Kim HY, Kim HJ. Effect of oral administration of Korean red ginseng on influenza A (H1N1) virus infection. J Ginseng Res 2011;35:104-110. https://doi.org/10.5142/jgr.2011.35.1.104
  7. Nah SY. Ginseng: recent advances and trends. Korean J Ginseng Sci 1997;21:1-12.
  8. Sun HX, Xie Y, Ye YP. Advances in saponin-based adjuvants. Vaccine 2009;27:1787-1796. https://doi.org/10.1016/j.vaccine.2009.01.091
  9. Jie YH, Cammisuli S, Baggiolini M. Immunomodulatory effects of Panax ginseng C.A. Meyer in the mouse. Agents Actions 1984;15:386-391. https://doi.org/10.1007/BF01972376
  10. Rivera E, Daggfeldt A, Hu S. Ginseng extract in aluminium hydroxide adjuvanted vaccines improves the antibody response of pigs to porcine parvovirus and Erysipelothrix rhusiopathiae. Vet Immunol Immunopathol 2003;91:19-27. https://doi.org/10.1016/S0165-2427(02)00269-6
  11. Skene CD, Sutton P. Saponin-adjuvanted particulate vaccines for clinical use. Methods 2006;40:53-59. https://doi.org/10.1016/j.ymeth.2006.05.019
  12. Roxas M, Jurenka J. Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. Altern Med Rev 2007;12:25-48.
  13. World Health Organization. Influenza (seasonal): fact sheet no. 211. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/index.html.
  14. Nichol KL. Improving infl uenza vaccination rates among adults. Cleve Clin J Med 2006;73:1009-1015. https://doi.org/10.3949/ccjm.73.11.1009
  15. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004;103:133-138. https://doi.org/10.1016/j.virusres.2004.02.025
  16. Centers for Disease Control and Prevention. Flu vaccine effectiveness: questions and answers for health professionals. Available from: http://www.cdc.gov/flu/professionals/vaccination/effectivenessqa.htm.
  17. Goodwin K, Viboud C, Simonsen L. Antibody response to infl uenza vaccination in the elderly: a quantitative review. Vaccine 2006;24:1159-1169. https://doi.org/10.1016/j.vaccine.2005.08.105
  18. Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza: United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010;59:1057-1062.
  19. Foster SL, Moore WP. High-dose infl uenza vaccination in the elderly. J Am Pharm Assoc (2003) 2010;50:546-547. https://doi.org/10.1331/JAPhA.2010.10529
  20. Herrera GA, Iwane MK, Cortese M, Brown C, Gershman K, Shupe A, Averhoff F, Chaves SS, Gargiullo P, Bridges CB. Influenza vaccine effectiveness among 50-64-yearold persons during a season of poor antigenic match between vaccine and circulating infl uenza virus strains: Colorado, United States, 2003-2004. Vaccine 2007;25:154-160. https://doi.org/10.1016/j.vaccine.2006.05.129
  21. Hu S, Concha C, Lin F, Persson Waller K. Adjuvant effect of ginseng extracts on the immune responses to immunisation against Staphylococcus aureus in dairy cattle. Vet Immunol Immunopathol 2003;91:29-37. https://doi.org/10.1016/S0165-2427(02)00264-7
  22. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938;27:493-497.
  23. Xu L, Bao L, Lv Q, Deng W, Ma Y, Li F, Zhan L, Zhu H, Ma C, Qin C. A single-amino-acid substitution in the HA protein changes the replication and pathogenicity of the 2009 pandemic A (H1N1) influenza viruses in vitro and in vivo. Virol J 2010;7:325. https://doi.org/10.1186/1743-422X-7-325
  24. Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J. Protective immunity against infl uenza H5N1 virus challenge in mice by intranasal coadministration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology 2008;380:412-420. https://doi.org/10.1016/j.virol.2008.08.002
  25. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685. https://doi.org/10.1038/227680a0
  26. Prabakaran M, Madhan S, Prabhu N, Geng GY, New R, Kwang J. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice. Antiviral Res 2010;86:180-187. https://doi.org/10.1016/j.antiviral.2010.02.315
  27. Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, Palese P. Cellular proteins in infl uenza virus particles. PLoS Pathog 2008;4:e1000085. https://doi.org/10.1371/journal.ppat.1000085
  28. Song X, Hu S. Adjuvant activities of saponins from traditional Chinese medicinal herbs. Vaccine 2009;27:4883-4890. https://doi.org/10.1016/j.vaccine.2009.06.033
  29. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984;308:457-460. https://doi.org/10.1038/308457a0
  30. Wu CA, Yang YW. Induction of cell death by saponin and antigen delivery. Pharm Res 2004;21:271-277. https://doi.org/10.1023/B:PHAM.0000016239.04067.66
  31. Rajput ZI, Hu SH, Xiao CW, Arijo AG. Adjuvant effects of saponins on animal immune responses. J Zhejiang Univ Sci B 2007;8:153-161. https://doi.org/10.1631/jzus.2007.B0153
  32. Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, Makarova N, Perez DR, Macdonald GH, McCullers JA. Distinct contributions of vaccineinduced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against infl uenza. Clin Vaccine Immunol 2006;13:981-990. https://doi.org/10.1128/CVI.00156-06
  33. Yasui H, Kiyoshima J, Hori T, Shida K. Protection against influenza virus infection of mice fed Bifidobacterium breve YIT4064. Clin Diagn Lab Immunol 1999;6:186-192.
  34. Mbawuike IN, Zhang Y, Couch RB. Control of mucosal virus infection by infl uenza nucleoprotein-specifi c CD8+ cytotoxic T lymphocytes. Respir Res 2007;8:44. https://doi.org/10.1186/1465-9921-8-44
  35. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8:958-969. https://doi.org/10.1038/nri2448
  36. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35. https://doi.org/10.1038/nri978
  37. Chen WH, Toapanta FR, Shirey KA, Zhang L, Giannelou A, Page C, Frieman MB, Vogel SN, Cross AS. Potential role for alternatively activated macrophages in the secondary bacterial infection during recovery from influenza. Immunol Lett 2012;141:227-234. https://doi.org/10.1016/j.imlet.2011.10.009

Cited by

  1. A comparative study of the adjuvanticity of Hansenula polymorpha, Saccharomyces cerevsiae and Yarrowia lipolytica in oral and nasal immunization with virus capsid antigens vol.35, pp.11, 2013, https://doi.org/10.1007/s10529-013-1273-8
  2. Ginsenoside Rb1 Protects Neonatal Rat Cardiomyocytes from Hypoxia/Ischemia Induced Apoptosis and Inhibits Activation of the Mitochondrial Apoptotic Pathway vol.2014, pp.1741-4288, 2014, https://doi.org/10.1155/2014/149195
  3. Korean red ginseng extract alleviates atherosclerotic lesions in apolipoprotein E knockout mice vol.23, pp.4, 2014, https://doi.org/10.1007/s10068-014-0174-5
  4. Proteomic Analysis of Anticancer TCMs Targeted at Mitochondria vol.2015, pp.1741-4288, 2015, https://doi.org/10.1155/2015/539260
  5. Red ginseng and H5N1 influenza infection vol.38, pp.3, 2014, https://doi.org/10.1016/j.jgr.2014.05.003
  6. Ginseng, the natural effectual antiviral: Protective effects of Korean Red Ginseng against viral infection vol.40, pp.4, 2012, https://doi.org/10.1016/j.jgr.2015.09.002
  7. Greater Efficacy of Black Ginseng (CJ EnerG) over Red Ginseng against Lethal Influenza A Virus Infection vol.11, pp.8, 2019, https://doi.org/10.3390/nu11081879
  8. Pharmacological effects of ginseng on infectious diseases vol.27, pp.5, 2012, https://doi.org/10.1007/s10787-019-00630-4